NCT06157242View on ClinicalTrials.gov

PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 10, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Bacterial Infections
Interventions
DRUG

Xeruborbactam Oral Prodrug

Experimental

DRUG

Ceftibuten

Experimental

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33136

University of Miami Clinical Pharmacology, Miami

All Listed Sponsors
collaborator

Shionogi Inc.

INDUSTRY

collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Qpex Biopharma, Inc.

INDUSTRY

NCT06157242 - PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment | Biotech Hunter | Biotech Hunter